EVH (Evolent Health) LT-Debt-to-Total-Asset: 0.52 (As of Mar. 2026)

What is Evolent Health LT-Debt-to-Total-Asset?

Evolent Health EVH -6.07% 65 LT-Debt-to-Total-Asset is 0.52 as of Mar. 2026. GuruFocus rates EVH with a GF Score™ of 65/100 and a GF Value™ of $11.07 (Possible Value Trap). The stock has 7 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Evolent Health's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.52.

Evolent Health's long-term debt to total assets ratio increased from Mar. 2025 (0.25) to Mar. 2026 (0.52). It may suggest that Evolent Health is progressively becoming more dependent on debt to grow their business.

Evolent Health (NYSE:EVH) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Evolent Health LT-Debt-to-Total-Asset Related Terms

Evolent Health LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Evolent Health's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evolent Health LT-Debt-to-Total-Asset Chart

Evolent Health Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.19

0.26

0.24

0.20

0.51

Evolent Health Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.25	0.27	0.43	0.51	0.52

65GF Score

Evolent Health Inc EVH

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Evolent Health LT-Debt-to-Total-Asset Calculation

Evolent Health's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	974.355	/	1899.236
	=	0.51

Evolent Health's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	976.646	/	1878.847
	=	0.52

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.52 mean?

Evolent Health (EVH) has a LT-Debt-to-Total-Asset of 0.52 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Evolent Health and its competitors.

Is Evolent Health's LT-Debt-to-Total-Asset too high?

Evolent Health's current LT-Debt-to-Total-Asset is 0.52. Overall, Evolent Health has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Evolent Health's LT-Debt-to-Total-Asset compare to PHR and CTEV?

Evolent Health's LT-Debt-to-Total-Asset of 0.52 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Healthcare Providers & Services company?

A good LT-Debt-to-Total-Asset depends on the Healthcare Providers & Services industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Evolent Health and its competitors. Evolent Health's current LT-Debt-to-Total-Asset is 0.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Evolent Health stock overvalued right now?

Based on GuruFocus' analysis, Evolent Health (EVH) is currently considered Possible Value Trap. The stock's GF Value™ is $11.07, compared to a current price of $5.42 — trading 51% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.52. Evolent Health's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Evolent Health (EVH), the current LT-Debt-to-Total-Asset is 0.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Evolent Health (EVH) Overvalued in 2026?

Based on GuruFocus' analysis, Evolent Health stock appears to be undervalued. The current stock price of $5.42 is trading 51% below its estimated GF Value™ of $11.07. GuruFocus considers Evolent Health to be Possible Value Trap.

Key valuation signals for EVH:

LT-Debt-to-Total-Asset: 0.52
GF Value™: $11.07 vs. price of $5.42 (51% below fair value)
GF Score™: 65/100 with 7 warning signs

No single metric tells the full story. See the EVH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Evolent Health Business Description

Industry Healthcare Healthcare Providers & Services

Comparable Companies PHR CTEV MDRX SOPH WEAV NRC HSTM TBRG SLP TALK VEEV ASX:PME BTSG TEM HQY TSE:2413 HNGE TXG DOCS WAY

Other Exchanges 9EH:Germany

Address 1812 North Moore Street, Suite 1705, Arlington, VA, USA, 22209

Website https://www.evolenthealth.com

Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The solutions provided by the company includes: Oncology, Cardiology, Musculoskeletal, Administrative Services, Advanced Illness, Genetic Testing, Physical Medicine, Radiology, and Surgical Management.

65GF Score

Get the complete analysis for EVH

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.42

Price

$11.07

GF Value

View EVH Analysis

See LT-Debt-to-Total-Asset data for all stocks →